Comparison of triazolam and placebo in the treatment of insomnia in depressed patients

R. A. Dominguez, A. F. Jacobson, B. J. Goldstein, R. M. Steinbook

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


A 4-week double-blind study compared triazolam and placebo in 78 depressed outpatients receiving imipramine. The diagnosis of major depressive disorder was established using DSM-III criteria. The baseline mean total score on the Hamilton Depression Rating Scale was over 26 for both groups. The imipramine dosage ranged from 50 to 300 milligrams per day. Patients were randomized to receive, along with imipramine, either triazolam 0.5 mg or placebo at night for 28 consecutive nights. Although insomnia improved in both the placebo and triazolam groups, the triazolam group showed significantly more improvement than the control group in most sleep parameters. Depressive symptoms improved equally and significantly for both groups; by week 4 the mean Hamilton Depression Rating Scale scores were 12.3 for both groups. Of the patients who dropped out of treatment because of side effects, twice as many were on placebo as on triazolam. The study results show triazolam to be effective in treating insomnia in depressed patients without diminishing the therapeutic effect of imipramine.

Original languageEnglish (US)
Pages (from-to)856-865
Number of pages10
JournalCurrent Therapeutic Research - Clinical and Experimental
Issue number5 I
StatePublished - Dec 1 1984

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Comparison of triazolam and placebo in the treatment of insomnia in depressed patients'. Together they form a unique fingerprint.

Cite this